Pathstone Holdings
PRCT icon

Pathstone Holdings’s Procept Biorobotics PRCT Stock Holding History

Pathstone Holdings’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$760K Sell
33,655
-14,123
-30% -$354K ﹤0.01% 1650
2026
Q1 		$1.19M Buy
47,778
+22,370
+88% +$630K ﹤0.01% 1319
2025
Q4 		$799K Buy
25,408
+8,283
+48% +$275K ﹤0.01% 1534
2025
Q3 		$611K Sell
17,125
-10,152
-37% -$464K ﹤0.01% 1673
2025
Q2 		$1.57M Sell
27,277
-1,394
-5% -$78.8K 0.01% 1134
2025
Q1 		$1.67M Buy
28,671
+10,254
+56% +$700K 0.01% 1084
2024
Q4 		$1.48M Buy
18,417
+15,620
+558% +$1.33M 0.01% 1149
2024
Q3 		$224K Buy
+2,797
New +$199K ﹤0.01% 2113

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pathstone Holdings's PRCT Position: Q2 2026 in Review

Pathstone Holdings reduced its Procept Biorobotics (PRCT) stake by 30% in Q2 2026, selling an estimated $354K and leaving 33,655 shares worth $760K. The position accounts for ﹤0.01% of the portfolio, ranked #1650.

Pathstone Holdings first reported a position in PRCT in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.67M in Q1 2025. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Pathstone Holdings held 33,655 shares of Procept Biorobotics worth $760K as of Q2 2026.
  • Pathstone Holdings sold 14,123 Procept Biorobotics shares in Q2 2026, an estimated $354K.
  • Procept Biorobotics made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1650 holding.
  • Pathstone Holdings first reported a position in Procept Biorobotics in Q3 2024 and has held it in 8 quarters since.
  • Pathstone Holdings's Procept Biorobotics position peaked at $1.67M in Q1 2025.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.